Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA – Research Report) on November 21 and set a price target of $4.00. The company’s shares closed yesterday at $0.46.
Gershell covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics, Crinetics Pharmaceuticals, and Alnylam Pharma. According to TipRanks, Gershell has an average return of -3.0% and a 33.49% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nucana with a $4.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.75 and a one-year low of $0.38. Currently, Nucana has an average volume of 70.11K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nucana (NCNA) Company Description:
NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology is consists of acelarin, NUC-3373, and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.
Read More on NCNA:
